Recombinant exenatide-4 - CSPC

Drug Profile

Recombinant exenatide-4 - CSPC

Alternative Names: rE4; rExenatide-4 - CSPC

Latest Information Update: 03 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CSPC Pharma
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 08 Aug 2017 CSPC ZhongQi Pharmaceutical plans a phase III trial for Type-2 diabetes mellitus (Treatment-experienced) (NCT03239119)
  • 21 Jan 2017 CSPC ZhongQi Pharmaceutical Technology completes a phase I trial in Type-2 diabetes mellitus (In volunteers) in China (NCT03199261)
  • 23 Dec 2016 CSPC ZhongQi Pharmaceutical Technology initiates enrolment in a phase I trial for Type-2 diabetes mellitus (In volunteers) in China (NCT03199261)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top